Serum IGF-1 Concentrations Change With Soy and Seaweed Supplements in Healthy Postmenopausal American Women

Jane Teas
University of South Carolina - Columbia

Mohammad R. Irhimeh

Susan Druker

Thomas G. Hurley
University of South Carolina - Columbia

James R. Hébert
University of South Carolina - Columbia, jhebert@sc.edu

See next page for additional authors

Follow this and additional works at: http://scholarcommons.sc.edu/sph_epidemiology_biomathetics_facpub

Part of the Public Health Commons

Publication Info
This is an electronic version of an article published in:
Nutrition and Cancer is available online at: www.tandfonline.com.
© 2011 Taylor & Francis.
Serum IGF-1 Concentrations Change With Soy and Seaweed Supplements in Healthy Postmenopausal American Women

Jane Teas,
Cancer Research Center of the University of South Carolina, Columbia, South Carolina, USA

Mohammad R. Irhimeh,
Save Sight Institute, Sydney Hospital, University of Sydney, Sydney, Australia

Susan Druker,
Department of Preventive Behavioral Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA

Thomas G. Hurley,
Cancer Research Center of the University of South Carolina, Columbia, South Carolina, USA; South Carolina Statewide Cancer Prevention and Control Program, Columbia, South Carolina, USA; and Department of Biostatistics and Epidemiology, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA

James R. Hébert,
Cancer Research Center of the University of South Carolina, Columbia, South Carolina, USA; South Carolina Statewide Cancer Prevention and Control Program, Columbia, South Carolina, USA; and Department of Biostatistics and Epidemiology, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA

Todd M. Savarese,
Department of Cancer Biology and Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts, USA

Mindy S. Kurzer
Department of Food Science and Nutrition, University of Minnesota, St. Paul, Minnesota, USA

Abstract

Insulin-like growth factor 1 (IGF-1) is an anabolic hormone important for growth and development. However, high-circulating serum concentrations in adults are associated with increased risk of postmenopausal breast cancer. Nutritional status and specific foods influence serum IGF-1 concentrations. Breast cancer incidence is typically low in Asian countries where soy is commonly consumed. Paradoxically, soy supplement trials in American women have reported significant increases in IGF-1. Seaweed also is consumed regularly in Asian countries where breast cancer risk is low. We investigated the possibility that seaweed could modify soy-associated increases in IGF-1 in American women. Thirty healthy postmenopausal women (mean age 58 yr) participated in this 14-wk double-blinded, randomized, placebo-controlled crossover clinical trial.
Participants consumed 5 g/day placebo or seaweed (Alaria esculenta) in capsules for 7 wk. During the 7th wk, a high-soy protein isolate powder was added (2 mg/kg body weight aglycone equivalent isoﬂavones). Overnight fasting blood samples were collected after each intervention period. Soy signiﬁcantly increased serum IGF-1 concentrations compared to the placebo (21.2 nmol/L for soy vs. 16.9 nmol/L for placebo; \( P = 0.0001 \)). The combination of seaweed and soy signiﬁcantly reduced this increase by about 40% (21.2 nmol/L for soy alone vs. 19.4 nmol/L; \( P = 0.01 \)). Concurrent seaweed and soy consumption may be important in modifying the effect of soy on IGF-1 serum concentrations.

**INTRODUCTION**

Breast cancer rates are remarkably different even among developed countries. Japanese women living in Japan have about one quarter the rate of breast cancer as that of women in other industrialized nations (1), and the differences are particularly evident after menopause, when breast cancer rates continue to rise with age elsewhere but plateau in Japan. The rate of breast cancer almost doubles in the first 10 years after Japanese women immigrate to the United States, and this difference is thought to be related to environmental and lifestyle factors, especially diet (2,3).

An important biomarker of breast cancer risk is serum insulin-like growth factor (IGF-1). A meta-analysis of 17 studies of breast cancer and serum IGF-1 concentrations reported that high serum concentrations of IGF-1 were associated with increased postmenopausal breast cancer risk (4). Laboratory data support a role for the IGF-1 signaling pathway in carcinogenesis, with increased DNA synthesis and decreased cell cycle regulation leading to inhibition of apoptosis (5). Blocking this pathway has been shown to benefit cancer patients (6).

Serum IGF-1 concentrations can be modified by diet, including dairy products and tomato-derived foods (7,8). In vivo trials with green tea and resveratrol also decreased serum concentrations (9,10). Clinical studies conducted in the United States, a non-soy-consuming culture, have reported increased IGF-1 with soy supplementation (11,12).

Seaweed has not been studied for its effects on IGF-1, although it shows antitumor activity in both in vitro and in vivo breast cancer studies (13–16). In further support for a role in breast cancer prevention, a case-control study of women in Korea reported that women with the highest seaweed intake had about half the rate of breast cancer as women who infrequently or never consumed seaweed (17). The best-studied mechanism for its antitumor activity is the high antioxidant effects observed in both laboratory and clinical settings (18–20). The antioxidants characteristic of seaweed include bioactive compounds not found in land plants, including fucoidan, fucoxanthin, and phlorotannins (21).

In this clinical trial conducted with American women, we investigated the importance of dietary seaweed and soy and their impact on several known biomarkers of breast cancer risk, including serum concentrations of IGF-1 and its main binding protein, IGFBP-3.

**EXPERIMENTAL METHODS**

**Study Population**

Data for this analysis were collected as part of a trial investigating the effects of seaweed and soy on a number of breast-cancer-related endpoints, including estrogens, phytoestrogens, and thyroid function (22,23). All participants were healthy postmenopausal European-American women living in central Massachusetts. This study was conducted...
according to the guidelines described in the Declaration of Helsinki, and all procedures involving human subjects/patients were approved by the University of Massachusetts Medical School Institutional Review Board. Written informed consent was obtained from all subjects/patients.

Inclusion criteria were: postmenopausal (self-reported cessation of menstruation for more than 1 yr); not allergic to seaweed, soy, shellfish, or iodine; non-smoking; euthyroid (no diagnosis or treatment for thyroid dysfunction within the previous 5 yr); negative for thyroid peroxidase (TPO) antibodies as determined by screening; no hormone replacement therapy or, for breast cancer survivors, no chemotherapy or radiation treatments within the preceding 6 mo; no history of cancer (other than breast cancer); no current gastrointestinal disorders or diagnosis of diabetes; omnivorous eating habits including meat and dairy products more than twice per wk; and no medications containing antibiotics or corticosteroids within the previous 3 mo. Women continued to eat their normal diets, avoiding seaweed and phytoestrogen-rich foods, and continued habitual intake of vitamins, supplements, and medications during the study.

Women were recruited by word of mouth, physician referrals, and through responses to a newspaper article. Thirty-three women were enrolled into the study and provided baseline data. Decreased IGF-1 has been noted in women taking Tamoxifen, so the 3 women who were taking antiestrogens (2 BCS and 1 NBC for osteoporosis) were excluded from the analyses. This left a final study sample of 30 women (mean age 58.4 yr, 95% CI 55.5–61.4), among whom 11 were breast cancer survivors (Stage 1 or 2 at diagnosis but with no evidence of disease at the time of the study) and 19 had never been diagnosed with breast cancer.

**Experimental Design and Dietary Treatments**

To minimize possible seasonal effects, all women began the study the same week in late October. The study used an unbiased, randomized, placebo-controlled crossover design. Prior to the first clinic visit, all eligible participants were assigned to a treatment group using a computer-generated random number table. Treatment arms were either 1) 7 wk of 5 g/day seaweed powder (10 capsules) or 20 7 wk of 5 g/day maltodextrin in 10 identical gelatin capsules followed by a 3-wk washout period and then crossed over to the alternate treatment arm (Fig. 1). During Week 7, women consumed a daily soy protein isolate supplement in addition to the 5 g/day seaweed or placebo. All capsules were taken with the last meal of the day.

Fasting blood samples were collected at the end of each treatment period. To assure blinded laboratory analysis, each patient at each clinic visit was assigned a unique random ID number.

**Seaweed and Placebo**

*Alaria esculenta* (L.) Greville grows along the northeastern shores of North America. It was chosen for its low-iodine content (95 μg/g) (22). The *Alaria* for this study was collected at maximum reproductive maturity in late June from the Sally Islands by Maine Seaweed Company (Stuben, ME), following standard collection protocols (22). A 5 g serving of dried *Alaria* harvested in the same area contains 54.6 kJ, 0.9 g protein, 7.5–9.8 μg folate, 475 μg iodine, 0.18 g fat, 2 g carbohydrate, 1.9 g fiber, 373 mg potassium, and 212 mg sodium (24). Maltrin M100 maltodextrin (Grain Processing Corporation, Muscatine, IA) was used as placebo, and 5 g/day provided 75.6 kJ of total energy.
The seaweed was milled and both the seaweed and placebo powders were encapsulated into identical gelatin capsules (Beehive Botanicals, Hayward, WI). No fillers or binders were added to the seaweed or placebo powder.

**Soy Protein Isolate**

A soy protein ingredient made with soy protein isolate [High Protein Nutritious Food Ingredient Powder (AB1.2 HG 20CA 29 Lot #G198-8)] was provided by Solae, LLC. (St. Louis, MO). It contained 1.43 mg/g total isoflavones (expressed as aglycone equivalents). A dose of 2 mg isoflavones/kg body weight was calculated for each woman. The mean dose was 100 g/day soy powder, providing 67 g of soy protein containing 85 mg genistein, 50 mg daidzein, and 8 mg glycitein.

**Blood Collection and Handling**

Blood samples were drawn from fasting participants between 6:30 and 10:30 by venipuncture at a consistent time for each subject at baseline and at the end of each treatment period. Serum was harvested within 1 h by low-speed centrifugation at 4°C and stored at −80°C.

**IGF-1 and IGFBP-3 Analyses**

Active IGF-1 and IGFBP-3 were measured with 2-site immunoradiometric assay (IRMA) (DSL-5600, Diagnostic Systems Laboratories, Inc., Webster, TX) in serum sample aliquots that had not been previously thawed following the manufacturer’s protocols. Laboratory personnel were unaware of the treatment status or breast cancer history of the study subjects.

**Statistical Analyses**

Statistical analyses followed the same procedures as in our two earlier studies (22,23). Simple descriptive statistics were used to characterize the study sample. Two women withdrew because of mild side effects that resolved when seaweed intake ceased: 1 had reactivated esophageal reflux and 1, with a history of allergic reactions to medications, developed a skin rash and itchy eyes. A third woman withdrew halfway through the study on the advice of her naturopath. All 3 women had participated in the first 3 data collection points and therefore had contributed meaningful data to analyses. Because our statistical models use all available data without imputation, the standard Intention to Treat approach (25) was justified and included all available data from these women.

To test the primary study hypotheses, a repeated-measures analysis of variance (ANOVA) was conducted using Proc Mixed in SAS. In these models, subject was fit as the repeated factor, while treatment group [4 levels: placebo, seaweed, soy, and SeaSoy (combination of seaweed and soy)], sequence of treatment administration, disease status, and age were fit as independent variables.

Individual models were run for IGF-1, IGFBP-3, and the IGF-1:IGFBP-3 ratio. Results are presented as least-squares means (LSMeans; these are the covariate-adjusted means obtained from the mixed model) with 95% confidence intervals (95% CI). Linear contrasts were created in Proc Mixed to test for the main effects of seaweed, soy, and SeaSoy relative to placebo. For the 3 main effects, the difference was calculated separately between the LSMeans for each treatment and the placebo. To test for the interaction effect of SeaSoy, the difference was calculated as the LSMean for SeaSoy—the sum of the LSMeans for seaweed and soy. Statistical significance was determined using a t-test of the Ho: the difference = 0 and was evaluated at $P = 0.05$. 

*Teas et al. Page 4*  
*Nutr Cancer. Author manuscript; available in PMC 2012 July 1.*
RESULTS

There were no significant differences in age, BMI [body mass index = weight(kg)/height(m)^2], weight, physical exercise, parity, breast cancer treatments, and baseline IGF-1 and IGFBP-3 between breast cancer survivors and the volunteers without a history of breast cancer (Table 1).

Although all values were within the normal range of IGF-1 (14.9–64.5 nmol/L), the mean serum concentration of the IGF-1 differed significantly by dietary intervention (Table 2). When taking the placebo, women had a mean IGF-1 serum concentration of 16.9 nmol/L, which significantly increased by about 25% after the soy supplement period (21.1 nmol/L; \( P < 0.0001 \)). The interaction term tested for synergy; that is, whether the influence of seaweed plus soy was different than simply additive. This was significant for IGF-1 when soy and seaweed were given together, halving the soy-driven increase in IGF-1 (19.4 for SeaSoy, 21.2 nmol/L for soy alone; \( P < 0.01 \)). Serum concentrations of the IGFBP-3 did not vary significantly with dietary treatment. The IGF-1 to IGFBP-3 ratio increased significantly with seaweed (0.86 compared to 0.108; \( P < 0.02 \)).

DISCUSSION

Evidence for an effect of soy on IGF-1 is inconsistent. Clinical studies of soy supplements in American women have reported significantly increased IGF-1 serum concentrations. This is counterintuitive, as soy is commonly eaten in Asia, where breast cancer rates are very low.

Three epidemiological studies of postmenopausal women in countries where seaweed is not a common daily food (Nether-lands, Singapore, and China) have reported no association between IGF-1 and soy intake (26–28).

Observational data from Japan indicate that tofu consumption is associated with decreased IGF-1 serum concentration (29). To investigate the relative impact of a Japanese and an Americanized diet on IGF-1, Takata and colleagues compared tofu consumption and IGF-1 concentrations of Japanese women in Japan, Japanese-American women living in Hawaii, and European-American women living in Hawaii (30). Tofu consumption in Japan was associated with an 11% decrease in IGF-1 serum concentration but made no difference for women in Hawaii. The authors attributed these differences to the wider context of a typical Japanese diet. In further support for the dietary context for soy metabolism, a recent study of post-menopausal women in Singapore reported a dose-response reduction in breast cancer risk with increasing consumption of fruits, vegetables, and soy (31).

The reasons for these discrepancies may be related to the use of soy powder rather than soy foods such as tofu, or it may be related to the presence or absence of other common foods in the diet. Seaweed is a common food in Japan and Korea, but less frequently consumed in other Asian countries. Japanese intake of seaweed, as estimated by the Japanese Ministry of Health, is 12 g/d (32). Green tea, another common food in Japan and Korea, has also been shown to significantly lower soy-induced increased IGF-1 in vivo (33).

The limitations of our study include using only one kind of seaweed, rather than a combination of several seaweeds as they are commonly consumed in Japan; using soy powder rather than soy foods; and focusing exclusively on European-American women. On the other hand, though these limitations may limit the applicability to Asian–Western differences in breast cancer risk, they may shed light on how soy powder and seaweeds are metabolized in a non-Western population. As the addition of soy protein powder to the American diet is more likely than daily inclusion of tofu, our results indicating the
importance of co-factor foods such as seaweed may be relevant in reducing breast cancer risk that might be associated with supplemental soy protein powders.

Acknowledgments

This study was funded by grants to JT from the Susan G Komen Foundation (Grant 9735) and the U.S. Army Medical Research and Materiel Command under DAMD 17-98-1-8207. The soy protein isolate was donated by Solae, LLC (formerly Protein Technologies, Inc., St. Louis, MO). Dr. Hébert was supported by an Established Investigator Award in Cancer Prevention and Control from the Cancer Training Branch of the National Cancer Institute (K05 CA136975).

References


FIG. 1.
Study design showing timing of the 4 data collection points.
### TABLE 1
Characteristics of the healthy postmenopausal women study participants (N = 30)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Breast Cancer Survivors</th>
<th>No History of Breast Cancer</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of volunteers</td>
<td>11</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Mean (95% CI)</td>
<td>60.1 (54.9–65.3)</td>
<td>57.5 (53.6–61.4)</td>
<td>0.39</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>60.1 (54.9–65.3)</td>
<td>57.5 (53.6–61.4)</td>
<td>0.39</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.1 (22.8–31.4)</td>
<td>26.6 (24.6–28.6)</td>
<td>0.80</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>71.8 (61.2–82.4)</td>
<td>72.3 (67.2–77.4)</td>
<td>0.92</td>
</tr>
<tr>
<td>Years postmenopausal (yr)</td>
<td>12.7 (5.2–20.3)</td>
<td>7.5 (3.9–11.2)</td>
<td>0.14</td>
</tr>
<tr>
<td>IGF-1 at baseline (nmol/L)</td>
<td>17.0 (12.6–21.3)</td>
<td>17.6 (14.1–21.2)</td>
<td>0.81</td>
</tr>
<tr>
<td>IGFBP-3 at baseline (nmol/L)</td>
<td>160.7 (127.2–194.2)</td>
<td>188.8 (164.1–213.6)</td>
<td>0.16</td>
</tr>
<tr>
<td>Years post-BC diagnosis (yr)</td>
<td>5.3 (2.3–8.3)</td>
<td>N/Aa</td>
<td></td>
</tr>
<tr>
<td>Physical exercise (h/wk)</td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>4 (36)</td>
<td>6 (32)</td>
<td></td>
</tr>
<tr>
<td>Low (≤60 min)</td>
<td>2 (18)</td>
<td>5 (26)</td>
<td></td>
</tr>
<tr>
<td>High (&gt;60 min)</td>
<td>5 (45%)</td>
<td>8 (42)</td>
<td></td>
</tr>
<tr>
<td>Parity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nulliparous</td>
<td>2 (18)</td>
<td>3 (16)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1 (9)</td>
<td>2 (11)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>4 (36)</td>
<td>4 (21)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1 (9)</td>
<td>6 (32)</td>
<td></td>
</tr>
<tr>
<td>&gt;3</td>
<td>3 (27)</td>
<td>4 (21)</td>
<td></td>
</tr>
<tr>
<td>Breast cancer treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>11 (100)</td>
<td>N/Aa</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>3 (27)</td>
<td>N/Aa</td>
<td></td>
</tr>
<tr>
<td>Radiation</td>
<td>5 (45)</td>
<td>N/Aa</td>
<td></td>
</tr>
</tbody>
</table>

*a N/A: not applicable.*
### TABLE 2

Comparison of IGF-1 and IGFBP-3 serum concentrations in healthy postmenopausal women on placebo, seaweed, soy, and seasoy treatments (N = 30)

| Serum Concentration | Placebo Mean (95% CI) | Seaweed Mean (95% CI) | Soy Mean (95% CI) | Seasoy Mean (95% CI) | P values
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF-1 (nmol/L)</td>
<td>16.9 (14.6–19.2)</td>
<td>18.1 (15.8–20.5)</td>
<td>21.2 (18.9–23.5)</td>
<td>19.4 (17.0–21.7)</td>
<td>0.15</td>
</tr>
<tr>
<td>IGFBP-3 (nmol/L)</td>
<td>191.9 (172.0–211.7)</td>
<td>174.4 (153.6–195.3)</td>
<td>209.5 (189.0–230.0)</td>
<td>198.4 (177.6–219.2)</td>
<td>0.18</td>
</tr>
<tr>
<td>IGF-1:IGFBP-3 ratio</td>
<td>0.086 (0.074–0.101)</td>
<td>0.108 (0.092–0.127)</td>
<td>0.098 (0.084–0.116)</td>
<td>0.098 (0.083–0.115)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

*a* The mean indicated in the table is for the after-treatment values. There were no changes in the baseline values and hence were not included in the table.

*b* Linear contrasts were used to test for the main effects and a synergistic interaction effects. For seasoy, the first P value is for the test relative to placebo, and the second is the test for a synergistic interaction.